07-08-2025
PharmAla Delivers MDMA to Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License
TORONTO, Aug. 07, 2025 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. ('PharmAla' or the 'Company') (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has completed customs clearance and delivery of over 500 capsules of the company's LaNeo 40mg MDMA to Merhavim Mental Health Centre of Beer Yaakov, Israel ('Merhavim').
'We believe that this delivery sets a precedent in terms of the innovative terms agreed-to with Merhavim – terms that allows researchers to explore new and complex mental health indications with less financial risk while allowing PharmAla to develop important intellectual property in a cost-effective manner,' said Nick Kadysh, CEO of PharmAla Biotech. 'However it also continues to show PharmAla's ability to work rapidly on behalf of our clients, with just 6 months between execution and delivery of the shipment – even with complexity in not only cross-border trade and tariff pressure, but also a significant conflict in the region.'
